JP2012514982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514982A5 JP2012514982A5 JP2011545537A JP2011545537A JP2012514982A5 JP 2012514982 A5 JP2012514982 A5 JP 2012514982A5 JP 2011545537 A JP2011545537 A JP 2011545537A JP 2011545537 A JP2011545537 A JP 2011545537A JP 2012514982 A5 JP2012514982 A5 JP 2012514982A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable antibody
- target
- tissue
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001519 tissue Anatomy 0.000 claims 17
- 230000027455 binding Effects 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 238000010494 dissociation reaction Methods 0.000 claims 8
- 230000005593 dissociations Effects 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- 229940088598 enzyme Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000000873 masking effect Effects 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 claims 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims 2
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000001759 Notch1 Receptor Human genes 0.000 claims 2
- 108010029755 Notch1 Receptor Proteins 0.000 claims 2
- 102000001756 Notch2 Receptor Human genes 0.000 claims 2
- 108010029751 Notch2 Receptor Proteins 0.000 claims 2
- 102000001760 Notch3 Receptor Human genes 0.000 claims 2
- 108010029756 Notch3 Receptor Proteins 0.000 claims 2
- 102000001753 Notch4 Receptor Human genes 0.000 claims 2
- 108010029741 Notch4 Receptor Proteins 0.000 claims 2
- 102100032702 Protein jagged-1 Human genes 0.000 claims 2
- 102100032733 Protein jagged-2 Human genes 0.000 claims 2
- 101710170213 Protein jagged-2 Proteins 0.000 claims 2
- -1 TMPRSS-3 / 4 Proteins 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102000005600 Cathepsins Human genes 0.000 claims 1
- 108010084457 Cathepsins Proteins 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 101000936738 Coturnix japonica Astacin-like metalloendopeptidase Proteins 0.000 claims 1
- 108010088842 Fibrinolysin Proteins 0.000 claims 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims 1
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 101000610980 Homo sapiens Tumor protein D52 Proteins 0.000 claims 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 claims 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 101000794562 Naegleria gruberi Calmodulin, flagellar Proteins 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 102100040418 Tumor protein D52 Human genes 0.000 claims 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 102000052502 human ELANE Human genes 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14410509P | 2009-01-12 | 2009-01-12 | |
| US14411009P | 2009-01-12 | 2009-01-12 | |
| US61/144,110 | 2009-01-12 | ||
| US61/144,105 | 2009-01-12 | ||
| US24944109P | 2009-10-07 | 2009-10-07 | |
| US24941609P | 2009-10-07 | 2009-10-07 | |
| US61/249,416 | 2009-10-07 | ||
| US61/249,441 | 2009-10-07 | ||
| PCT/US2010/020820 WO2010081173A2 (en) | 2009-01-12 | 2010-01-12 | Modified antibody compositions, methods of making and using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146530A Division JP6271476B2 (ja) | 2009-01-12 | 2015-07-24 | 改変した抗体組成物、それを作製および使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012514982A JP2012514982A (ja) | 2012-07-05 |
| JP2012514982A5 true JP2012514982A5 (enExample) | 2012-12-06 |
| JP5851842B2 JP5851842B2 (ja) | 2016-02-03 |
Family
ID=42317225
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545537A Active JP5851842B2 (ja) | 2009-01-12 | 2010-01-12 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2015146530A Active JP6271476B2 (ja) | 2009-01-12 | 2015-07-24 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2017157121A Active JP6571730B2 (ja) | 2009-01-12 | 2017-08-16 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2019027222A Active JP6860601B2 (ja) | 2009-01-12 | 2019-02-19 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2020156514A Active JP7221259B2 (ja) | 2009-01-12 | 2020-09-17 | 改変した抗体組成物、それを作製および使用する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146530A Active JP6271476B2 (ja) | 2009-01-12 | 2015-07-24 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2017157121A Active JP6571730B2 (ja) | 2009-01-12 | 2017-08-16 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2019027222A Active JP6860601B2 (ja) | 2009-01-12 | 2019-02-19 | 改変した抗体組成物、それを作製および使用する方法 |
| JP2020156514A Active JP7221259B2 (ja) | 2009-01-12 | 2020-09-17 | 改変した抗体組成物、それを作製および使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US20100189651A1 (enExample) |
| EP (2) | EP3543256A1 (enExample) |
| JP (5) | JP5851842B2 (enExample) |
| CN (2) | CN106995495A (enExample) |
| AU (4) | AU2010203353B2 (enExample) |
| BR (1) | BRPI1006141B8 (enExample) |
| CA (1) | CA2749339A1 (enExample) |
| RU (1) | RU2636046C2 (enExample) |
| WO (1) | WO2010081173A2 (enExample) |
Families Citing this family (264)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP3492488A1 (en) * | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| WO2010081173A2 (en) * | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| EP2398504B1 (en) | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| US8772459B2 (en) | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| EA034333B1 (ru) | 2010-11-30 | 2020-01-29 | Дженентек, Инк. | Варианты антитела для переноса соединения через гематоэнцефалический барьер |
| EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
| US9107887B2 (en) | 2011-03-10 | 2015-08-18 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| AU2013251310B2 (en) * | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US20150166654A1 (en) | 2012-05-30 | 2015-06-18 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| US9856314B2 (en) * | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| CA2876904C (en) * | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| BR112015003032B1 (pt) | 2012-08-13 | 2023-03-28 | Genentech, Inc | Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| WO2014052462A2 (en) * | 2012-09-25 | 2014-04-03 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| CN112162094A (zh) * | 2013-01-04 | 2021-01-01 | 西托姆克斯治疗公司 | 用于检测生物系统中的蛋白酶活性的组合物和方法 |
| RU2519546C1 (ru) * | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| EP2970498A4 (en) * | 2013-03-15 | 2016-11-23 | Bayer Healthcare Llc | PRODUCT ANTIBODIES DIRECTED AGAINST THE INHIBITOR OF THE PATHWAY OF TISSUE FACTOR |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| EP3003370B1 (en) | 2013-05-28 | 2020-01-22 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| EP3003387A1 (en) | 2013-06-04 | 2016-04-13 | Cytomx Therapeutics Inc. | Compositions and methods for conjugating activatable antibodies |
| CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| WO2015023927A2 (en) * | 2013-08-16 | 2015-02-19 | University Of Rochester | Composition and method for detection of nanomaterials |
| IL291329B1 (en) * | 2013-09-25 | 2025-09-01 | Cytomx Therapeutics Inc | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| TW202446953A (zh) | 2013-12-04 | 2024-12-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| CA2936377A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating egfr expressing tumors |
| CN106459153B (zh) | 2014-01-31 | 2021-12-21 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
| CN106459990B (zh) | 2014-02-07 | 2021-06-01 | 麦克马斯特大学 | 三功能t细胞抗原偶联物及其制备方法和用途 |
| KR102030891B1 (ko) * | 2014-02-12 | 2019-10-11 | 제넨테크, 인크. | 항-재기드1 항체 및 사용 방법 |
| US20160230202A1 (en) * | 2014-03-11 | 2016-08-11 | Eric William Olle | Process for Generating Synthetic Engineered Recombinant Proteins for Vaccination, Diagnosis and Treatment of Disease |
| CA2947605A1 (en) | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2016004383A1 (en) * | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| EP3253419A1 (en) | 2015-02-02 | 2017-12-13 | The University of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| KR102790523B1 (ko) | 2015-02-24 | 2025-04-02 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| HK1250997A1 (zh) | 2015-05-01 | 2019-01-18 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
| AU2016257929B2 (en) | 2015-05-04 | 2022-10-20 | Cytomx Therapeutics, Inc | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| US11400157B2 (en) | 2015-05-13 | 2022-08-02 | Chugai Seiyaku Kabushiki Kaisha | Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| CA2985818A1 (en) | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| WO2017019729A1 (en) | 2015-07-27 | 2017-02-02 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| JP6898303B2 (ja) | 2015-08-07 | 2021-07-07 | エーエルエックス オンコロジー インコーポレイテッド | Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物 |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| BR102016018074A2 (pt) | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| US10758886B2 (en) * | 2015-09-14 | 2020-09-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Conditioned surfaces for in situ molecular array synthesis |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| US11472876B2 (en) | 2015-11-02 | 2022-10-18 | Bioatla, Inc. | Conditionally active polypeptides |
| CA3005070A1 (en) | 2015-11-11 | 2017-05-18 | Serimmune Inc. | Methods and compositions for assessing antibody specificities |
| AU2016358296B2 (en) | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| CN105601751B (zh) * | 2016-02-01 | 2019-06-07 | 中国人民解放军第三军医大学 | 一种重组蛋白Vo及其制备方法和应用 |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| CA3014645C (en) | 2016-02-29 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2017205560A1 (en) * | 2016-05-27 | 2017-11-30 | Albert Einstein College Of Medicine, Inc. | Methods for treating cancer by targeting vcam1 and maea |
| WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| WO2018022957A1 (en) * | 2016-07-29 | 2018-02-01 | Tarveda Therapeutics, Inc. | T cell binding conjugates and methods of use |
| MX2019002474A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 |
| CN110177875B (zh) * | 2016-11-28 | 2023-11-28 | 中外制药株式会社 | 包含抗原结合结构域和运送部分的多肽 |
| CA3039316A1 (en) * | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN110036034A (zh) | 2016-12-09 | 2019-07-19 | 西雅图遗传学公司 | 卷曲螺旋掩蔽的二价抗体 |
| CN106519034B (zh) | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | 抗pd-1抗体及其用途 |
| CA3048467A1 (en) * | 2016-12-29 | 2018-07-05 | Development Center For Biotechnology | Klk6-mediated cns-specific antibody prodrug activation |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| AU2018225164A1 (en) * | 2017-02-22 | 2019-09-19 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| AU2018231127A1 (en) * | 2017-03-09 | 2019-09-19 | Cytomx Therapeutics, Inc. | CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| CA3059542A1 (en) * | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
| US12460208B2 (en) | 2017-04-18 | 2025-11-04 | Parr Biotechnology Co., Ltd. | Immunomodulatory polynucleotides and uses thereof |
| CN108728444A (zh) | 2017-04-18 | 2018-11-02 | 长春华普生物技术股份有限公司 | 免疫调节性多核苷酸及其应用 |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2018213335A1 (en) * | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
| MX2019013648A (es) | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| CA3068318A1 (en) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | Branched multi-functional macromonomers and related polymers and uses thereof |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| WO2019018828A1 (en) | 2017-07-20 | 2019-01-24 | Cytomx Therapeutics, Inc. | METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF |
| KR102003594B1 (ko) * | 2017-08-08 | 2019-07-24 | 숙명여자대학교산학협력단 | 염증 반응 매개 신혈관생성 질환 진단용 조성물 |
| US11623965B2 (en) * | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| MX2020002198A (es) | 2017-08-30 | 2020-07-20 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. |
| CN111315773A (zh) * | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| MX2020002667A (es) | 2017-09-08 | 2020-08-03 | Maverick Therapeutics Inc | Proteinas de unión condicionalmente activadas restringidas. |
| WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| PH12020550417A1 (en) | 2017-10-14 | 2021-04-12 | Abbvie Inc | Anti-cd71 activatable antibody drug conjugates and methods of use thereof |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| BR112020010450A2 (pt) | 2017-11-28 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora |
| WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| AR113862A1 (es) * | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| MX2020006297A (es) | 2017-12-15 | 2020-12-07 | Aleta Biotherapeutics Inc | Variantes de cd19. |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| WO2019126576A1 (en) | 2017-12-21 | 2019-06-27 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
| WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| IL323061A (en) | 2018-04-11 | 2025-10-01 | Inhibrx Biosciences Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| WO2019213444A1 (en) | 2018-05-02 | 2019-11-07 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| EP3787691A1 (en) | 2018-05-04 | 2021-03-10 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| WO2019222283A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| US12077577B2 (en) | 2018-05-30 | 2024-09-03 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| EP3802831A4 (en) * | 2018-05-30 | 2022-07-27 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
| EP3816182A4 (en) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
| BR112021001616A2 (pt) | 2018-07-31 | 2021-05-04 | Amgen Inc. | formulações farmacêuticas de anticorpos mascarados |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| US10988491B2 (en) | 2018-08-17 | 2021-04-27 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| TW202506736A (zh) | 2018-10-11 | 2025-02-16 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| MX2021005116A (es) | 2018-11-02 | 2021-07-15 | Cytomx Therapeutics Inc | Anticuerpos activables anti-cd166 y metodos de uso de estos. |
| CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| AU2019395266A1 (en) * | 2018-12-14 | 2021-06-17 | Proviva Therapeutics (Hong Kong) Limited | IL-15 compositions and methods of use thereof |
| BR112021012631A2 (pt) * | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| WO2020176672A1 (en) | 2019-02-26 | 2020-09-03 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| CN120484127A (zh) | 2019-03-05 | 2025-08-15 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| AU2020234785A1 (en) | 2019-03-13 | 2021-08-19 | Merck Sharp & Dohme Llc | Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents |
| WO2020191306A1 (en) | 2019-03-21 | 2020-09-24 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| IL286846B2 (en) | 2019-04-26 | 2025-06-01 | Immunogen Inc | Camptothecin derivatives |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| WO2020236679A1 (en) * | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| JP2022533791A (ja) | 2019-05-20 | 2022-07-25 | マサチューセッツ インスティテュート オブ テクノロジー | ボロン酸エステルプロドラッグおよびそれらの使用 |
| US11613564B2 (en) | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
| US20220306727A1 (en) | 2019-06-05 | 2022-09-29 | Seagen Inc. | Methods of Purifying Masked Antibodies |
| US20220233709A1 (en) | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| KR20220017430A (ko) | 2019-06-05 | 2022-02-11 | 추가이 세이야쿠 가부시키가이샤 | 항체 절단 부위 결합 분자 |
| WO2020251878A1 (en) | 2019-06-11 | 2020-12-17 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| EP3983440A1 (en) | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer |
| CN114173815A (zh) | 2019-06-13 | 2022-03-11 | 西托姆克斯治疗公司 | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的联合疗法中的用途 |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| EP4382129A3 (en) | 2019-06-17 | 2024-07-03 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| WO2021061867A1 (en) | 2019-09-23 | 2021-04-01 | Cytomx Therapeutics, Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| WO2021097376A1 (en) | 2019-11-14 | 2021-05-20 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US12064507B2 (en) | 2019-11-19 | 2024-08-20 | Provectus Pharmatech, Inc. | Composition and method for oral treatment of leukemia |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| TW202140570A (zh) * | 2020-01-23 | 2021-11-01 | 瑞士商天演藥業公司 | 具有Ｆｃ突變之異二聚蛋白質 |
| CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| AU2021240872A1 (en) * | 2020-03-23 | 2022-11-17 | Zymeworks Bc Inc. | Masked IL12 fusion proteins and methods of use thereof |
| KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| CN115667523A (zh) | 2020-04-10 | 2023-01-31 | 西托姆克斯治疗公司 | 可活化细胞因子构建体和相关组合物以及方法 |
| CN111951884B (zh) * | 2020-07-10 | 2022-03-22 | 中南大学 | 蛋白质小分子结合口袋上关键柔性氨基酸的识别方法 |
| ES3040950T3 (en) | 2020-08-11 | 2025-11-06 | Janux Therapeutics Inc | Cleavable linker compositions and methods |
| US20220089642A1 (en) * | 2020-09-17 | 2022-03-24 | City Of Hope | Fc Receptor-ACE2 Conjugates and Use Thereof |
| JP2023548310A (ja) * | 2020-10-30 | 2023-11-16 | アバクタ・ライフ・サイエンシーズ・リミテッド | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート |
| JP2023548136A (ja) * | 2020-10-30 | 2023-11-15 | アバクタ・ライフ・サイエンシーズ・リミテッド | 酵素活性化血清半減期延長型治療用コンジュゲート |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| CA3175637A1 (en) * | 2021-04-16 | 2022-10-20 | Aru NARENDRAN | Composition and method for oral treatment of leukemia |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| KR20240037892A (ko) | 2021-06-01 | 2024-03-22 | 트리움비라 이뮤놀로직스 유에스에이, 인크. | 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도 |
| EP4329794A2 (en) | 2021-06-18 | 2024-03-06 | Nammi Therapeutics, Inc. | Fusion protein composition(s) comprising masked type i interferons (ifn? and ifn?) for use in the treatment of cancer and methods thereof |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
| EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
| WO2023034825A1 (en) | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| US20240376200A1 (en) | 2021-09-24 | 2024-11-14 | Seagen Inc. | Improved Antibody Masking Domains |
| CA3233707A1 (en) | 2021-10-08 | 2023-04-13 | Alexey Yevgenyevich Berezhnoy | Activatable cytokine constructs and combination methods |
| JP2024537101A (ja) | 2021-10-08 | 2024-10-10 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| AU2022367525A1 (en) | 2021-10-15 | 2024-05-02 | Amgen Inc. | Activatable polypeptide complex |
| US20230183382A1 (en) | 2021-10-15 | 2023-06-15 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| WO2023064945A2 (en) * | 2021-10-15 | 2023-04-20 | Harpoon Therapeutics, Inc. | Conditional activation of immunoglobulin molecules |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| CN118401555A (zh) * | 2021-12-09 | 2024-07-26 | 信华生物药业(广州)有限公司 | 抗体掩蔽物及其用途 |
| KR20240141757A (ko) | 2022-02-09 | 2024-09-27 | 다이이찌 산쿄 가부시키가이샤 | 환경 응답성 마스킹 항체 및 그 이용 |
| CA3244052A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | ACTIVABLE IL-18 POLYPEPTIDES |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| EP4499685A1 (en) * | 2022-03-25 | 2025-02-05 | CytomX Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| EP4504257A1 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech Inc | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| KR20250011922A (ko) | 2022-05-16 | 2025-01-22 | 비온디스 비.브이. | 신규한 차폐된 항체 |
| CN119630428A (zh) | 2022-07-12 | 2025-03-14 | 西托姆克斯治疗公司 | Epcam免疫缀合物及其用途 |
| AR130076A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| EP4565690A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024031034A2 (en) * | 2022-08-05 | 2024-02-08 | Staidson Biopharma Inc. | A novel il-15r alpha fc fusion protein and uses thereof |
| WO2024150175A1 (en) * | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024173795A1 (en) * | 2023-02-17 | 2024-08-22 | California Institute Of Technology | Activatable drug conjugates and therapeutic applications thereof |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025150556A1 (ja) * | 2024-01-11 | 2025-07-17 | 第一三共株式会社 | 環境応答性ペプチドを利用したタンパク質の製造方法 |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5686121A (en) * | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US5306731A (en) * | 1985-06-14 | 1994-04-26 | Massachusetts Eye And Ear Infirmary | Method and products for treating the eye |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4952394A (en) * | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5144012A (en) * | 1988-08-08 | 1992-09-01 | Eli Lilly And Company | Cytotoxic drug conjugates |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| JPH02100685A (ja) * | 1988-10-05 | 1990-04-12 | Res Dev Corp Of Japan | ポリペプチド分泌発現ベクター，該ベクターで形質転換した微生物及び該微生物によるポリペプチドの製造 |
| US5010176A (en) * | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| US5162218A (en) * | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
| KR900701847A (ko) | 1988-11-18 | 1990-12-04 | 원본미기재 | 복합 폴리펩티드, 그들의 제조 방법 및 사용 방법 |
| KR0162259B1 (ko) * | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| US5459061A (en) | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) * | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5272253A (en) | 1991-07-01 | 1993-12-21 | Eli Lilly And Company | Cluster conjugates of drugs with antibodies |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| US6107059A (en) * | 1992-04-29 | 2000-08-22 | Affymax Technologies N.V. | Peptide library and screening method |
| DK0586002T3 (da) | 1992-08-18 | 2000-06-19 | Centro Inmunologia Molecular | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho |
| WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| US5834247A (en) * | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
| US5679548A (en) * | 1993-02-02 | 1997-10-21 | The Scripps Research Institute | Methods for producing polypeptide metal binding sites and compositions thereof |
| AU6235294A (en) * | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing polypeptide binding sites |
| US5556623A (en) * | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| WO1994025616A1 (en) | 1993-04-28 | 1994-11-10 | Worcester Foundation For Experimental Biology | Cell-targeted lytic pore-forming agents |
| US5777078A (en) | 1993-04-28 | 1998-07-07 | Worcester Foundation For Experimental Biology | Triggered pore-forming agents |
| JPH09503381A (ja) * | 1993-07-09 | 1997-04-08 | ジ・インスティテュート・オブ・キャンサー・リサーチ | プロテインチロシンキナーゼ及びそのリガンド |
| GB9322156D0 (en) | 1993-10-27 | 1993-12-15 | Univ Newcastel Upon Tyne | Activation of molecules |
| US5733757A (en) * | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5468785A (en) * | 1994-04-15 | 1995-11-21 | University Of Akron | Cobaloxime photoinitiated free radical polymerizations |
| US5686600A (en) | 1994-06-28 | 1997-11-11 | Novartis Finance Corporation | Antibodies which bind to insect gut proteins and their use |
| DK0769967T3 (da) | 1994-08-19 | 2008-03-31 | Wallone Region | Konjugater der omfatter et antitumormiddel, og anvendelse heraf |
| EP0706799B1 (en) | 1994-09-16 | 2001-11-14 | MERCK PATENT GmbH | Immunoconjugates II |
| US5877155A (en) | 1995-03-17 | 1999-03-02 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DE69636015T2 (de) | 1995-05-03 | 2007-01-04 | Bioenhancementsments Ltd. | Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| CA2265454A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| US5990286A (en) * | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| ES2236634T3 (es) * | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998048837A1 (en) * | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| WO1998049307A1 (en) * | 1997-05-01 | 1998-11-05 | Zymogenetics, Inc. | Mammalian cytokine-like receptor |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998052966A1 (en) * | 1997-05-19 | 1998-11-26 | The Johns Hopkins University School Of Medecine | Tissue specific prodrug |
| AU8513198A (en) * | 1997-07-25 | 1999-02-16 | Du Pont Pharmaceuticals Company | Aggrecan degrading metallo proteases |
| KR100230578B1 (ko) * | 1997-07-25 | 1999-12-01 | 허영섭 | 포스포리불로키나제를 융합파트너로 이용하는 재조합 인간 부갑상선호르몬의 발현벡터 |
| US20030166107A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) * | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| JP4460155B2 (ja) * | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| CA2335324A1 (en) | 1998-07-17 | 2000-01-27 | Genetag Technology, Inc. | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
| US7157418B1 (en) * | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
| ES2265693T3 (es) | 1998-10-16 | 2007-02-16 | Biogen Idec Ma Inc. | Proteinas de fusion con interferon-beta y usos. |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6534061B1 (en) * | 1999-04-12 | 2003-03-18 | Genentech, Inc. | Tumor necrosis factor receptor homologs and nucleic acids encoding the same |
| IL129427A0 (en) * | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| US6268488B1 (en) * | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
| US20040146516A1 (en) * | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| US6903196B1 (en) * | 1999-06-17 | 2005-06-07 | Utah Ventures Ii, L.P. | Methods for identifying and isolating tissue-specific lumen-exposed molecules |
| EP2977063A1 (en) | 1999-06-25 | 2016-01-27 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| DE60045247D1 (de) * | 1999-07-28 | 2010-12-30 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US20050208558A1 (en) * | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
| DE19952956A1 (de) * | 1999-11-03 | 2001-05-17 | Acgt Progenomics Ag | Verfahren zur Verbindung von molekularen Substanzen |
| US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| CA2404988A1 (fr) * | 2000-04-11 | 2001-10-18 | Institut Pasteur | Genome de listeria monocytogenes, polypeptides et utilisations |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| US7514067B2 (en) * | 2000-04-25 | 2009-04-07 | President And Fellows Of Harvard College | Methods for tumor diagnosis and therapy |
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| JP2003534387A (ja) * | 2000-06-01 | 2003-11-18 | ユニべルシテ・カトリック・ドゥ・ルベン | 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法 |
| US6625945B2 (en) * | 2000-08-08 | 2003-09-30 | Alfred D. Commins | Balanced, multi-stud hold-down |
| US8314060B2 (en) * | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| EP1315840A4 (en) * | 2000-09-08 | 2005-11-02 | Univ Texas | BIOPANNING AND RAPID ANALYSIS OF SELECTIVE INTERACTIVE LIGANDS (BRASIL) |
| DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| EP1349943A2 (en) | 2001-01-04 | 2003-10-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Detection of protein conformation using a split ubiquitin reporter system |
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002060488A1 (en) | 2001-01-30 | 2002-08-08 | Universite Catholique De Louvain | Anti-tumor compounds |
| AU2002233340B2 (en) * | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| JP2004519233A (ja) | 2001-02-19 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 免疫原性の低減された修飾された抗ｅｇｆｒ抗体 |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| GB0118155D0 (en) * | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| JP4689956B2 (ja) | 2001-08-01 | 2011-06-01 | ユニバーシティ オブ ブリストル | 増殖因子イソ型 |
| US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030134824A1 (en) * | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
| AU2002366303B2 (en) * | 2001-12-17 | 2007-09-20 | University College Cardiff Consultants Limited | Enzymatic cleavable reagents for specific delivery to disease sites |
| AU2003217415B2 (en) | 2002-02-14 | 2009-01-08 | William J Rutter | Chimeric molecules for cleavage in a treated host |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| NZ536420A (en) * | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| CN1665932B (zh) * | 2002-04-30 | 2010-12-15 | 株式会社载体研究所 | 具有修饰的蛋白酶依赖向性的载体 |
| US20040109855A1 (en) * | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| JP4351430B2 (ja) | 2002-10-04 | 2009-10-28 | 財団法人癌研究会 | ナノ黒鉛構造体に結合能を有するペプチド |
| EP1572242B1 (en) * | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| AU2004248138B2 (en) * | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| US20050009110A1 (en) | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| EP1664115A2 (en) * | 2003-08-01 | 2006-06-07 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
| EP1668114B1 (en) * | 2003-08-18 | 2009-11-04 | The Regents of the University of California | Polypeptide display libraries and methods of making and using thereof |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7985401B2 (en) * | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| WO2005051315A2 (en) * | 2003-11-24 | 2005-06-09 | The Regents Of The University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| WO2005067980A2 (en) * | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| GB0404187D0 (en) * | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| WO2005090407A1 (en) | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| EP1579873A1 (en) | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| WO2006055689A2 (en) * | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
| EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | A BLOODED ELEMENT WHICH IS SELECTLY Degraded in TUMOR TISSUE |
| WO2006108052A2 (en) * | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| DE102005036542A1 (de) | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| WO2007026972A2 (en) | 2005-09-01 | 2007-03-08 | Canon Kabushiki Kaisha | Binding protein molecule |
| JP4567563B2 (ja) | 2005-09-22 | 2010-10-20 | 富士通株式会社 | 携帯端末装置、ヒンジ装置、筒状部材及び光通信システム |
| EP1770099A1 (en) | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| WO2007064759A2 (en) * | 2005-11-29 | 2007-06-07 | The Scripps Research Institute | Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| BRPI0619463A2 (pt) | 2005-12-06 | 2013-01-08 | Domantis Ltd | ligando, uso do mesmo, mÉtodos para tratar cÂncer e para administrar um tratamento anti-vegf e tratamento anti-egfr a um indivÍduo, composiÇço, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodo para produzir um ligando, polipeptÍdeo de domÍnio variÁvel simples de imunoglobulina, e, antagonista de egfr |
| GB0604187D0 (en) | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
| CA2645347A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| WO2007106415A2 (en) | 2006-03-10 | 2007-09-20 | Massachusetts Institute Of Technology | Triggered self-assembly conjugates and nanosystems |
| US7118159B1 (en) | 2006-03-15 | 2006-10-10 | Gary Randall Andrews | Convertible tonneau cover |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| JP4959226B2 (ja) * | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| CA2658612C (en) * | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
| WO2008052322A1 (en) * | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers |
| EP1930342B1 (en) * | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| WO2008131258A2 (en) * | 2007-04-19 | 2008-10-30 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Pactamycin biosynthetic gene cluster |
| US20080317677A1 (en) | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
| MX2010001194A (es) * | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| US8317505B2 (en) * | 2007-08-21 | 2012-11-27 | Johnson & Johnson Vision Care, Inc. | Apparatus for formation of an ophthalmic lens precursor and lens |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| EP3492488A1 (en) * | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| KR101661770B1 (ko) | 2007-09-21 | 2016-10-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함 |
| GEP20156390B (en) | 2008-01-03 | 2015-11-10 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
| EP2356131A4 (en) | 2008-12-08 | 2012-09-12 | Tegopharm Corp | MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS |
| US20110178279A1 (en) | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| WO2010081173A2 (en) * | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US20120121613A1 (en) | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| WO2010085845A1 (en) | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
| HRP20230487T1 (hr) | 2009-02-13 | 2023-07-21 | Immunomedics, Inc. | Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| CN102413843A (zh) * | 2009-03-05 | 2012-04-11 | 阿森迪斯药物股份有限公司 | 干扰素α载体前药 |
| WO2011015921A1 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant cetuximab |
| WO2011015918A2 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vectors and compounds for expression of recombinant cetuximab |
| WO2011101435A1 (en) | 2010-02-19 | 2011-08-25 | Novo Nordisk A/S | Activatable constructs |
| WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
| US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
| AU2013251310B2 (en) | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| SG10201908685QA (en) * | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
-
2010
- 2010-01-12 WO PCT/US2010/020820 patent/WO2010081173A2/en not_active Ceased
- 2010-01-12 CN CN201710181616.7A patent/CN106995495A/zh active Pending
- 2010-01-12 EP EP19153924.6A patent/EP3543256A1/en active Pending
- 2010-01-12 JP JP2011545537A patent/JP5851842B2/ja active Active
- 2010-01-12 CN CN201080011779.7A patent/CN102482347B/zh active Active
- 2010-01-12 AU AU2010203353A patent/AU2010203353B2/en active Active
- 2010-01-12 EP EP10729683.2A patent/EP2385955B1/en active Active
- 2010-01-12 BR BRPI1006141A patent/BRPI1006141B8/pt active IP Right Grant
- 2010-01-12 RU RU2011133819A patent/RU2636046C2/ru active
- 2010-01-12 CA CA2749339A patent/CA2749339A1/en active Pending
- 2010-01-12 US US12/686,344 patent/US20100189651A1/en not_active Abandoned
-
2011
- 2011-12-09 US US13/315,623 patent/US8563269B2/en active Active
-
2012
- 2012-04-25 US US13/455,924 patent/US8513390B2/en active Active
-
2013
- 2013-03-04 US US13/784,407 patent/US20130309230A1/en not_active Abandoned
- 2013-09-26 US US14/038,232 patent/US9453078B2/en active Active
-
2015
- 2015-07-24 JP JP2015146530A patent/JP6271476B2/ja active Active
-
2016
- 2016-04-28 US US15/140,944 patent/US10059762B2/en active Active
- 2016-08-24 US US15/245,859 patent/US10118961B2/en active Active
- 2016-09-06 AU AU2016225810A patent/AU2016225810C1/en active Active
-
2017
- 2017-08-16 JP JP2017157121A patent/JP6571730B2/ja active Active
-
2018
- 2018-08-10 AU AU2018214147A patent/AU2018214147B2/en active Active
- 2018-08-23 US US16/110,597 patent/US10875913B2/en active Active
-
2019
- 2019-02-19 JP JP2019027222A patent/JP6860601B2/ja active Active
-
2020
- 2020-05-13 AU AU2020203143A patent/AU2020203143B2/en active Active
- 2020-09-17 JP JP2020156514A patent/JP7221259B2/ja active Active
- 2020-10-22 US US17/077,778 patent/US20210284721A1/en not_active Abandoned
-
2023
- 2023-12-29 US US18/400,894 patent/US20240228603A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012514982A5 (enExample) | ||
| RU2011133819A (ru) | Композиции модифицированных антител, способы их получения и применения | |
| JP2021178823A5 (enExample) | ||
| JP2017523176A5 (enExample) | ||
| JP2022046569A5 (enExample) | ||
| JP2015516813A5 (enExample) | ||
| Wels et al. | Construction, bacterial expression and characterization of a bifunctional single–chain antibody–phosphatase fusion protein targeted to the human ERBB–2 receptor | |
| CN112041348B (zh) | 抗cd73抗pd-l1双特异性抗体 | |
| CN101573382B (zh) | 针对人抗苗勒激素ⅱ型受体（amhr-ⅱ）的单克隆抗体 | |
| KR20140071501A (ko) | Ｓｐａｒｃ 결합 ｓｃｆｖｓ | |
| CN114450297A (zh) | Il-2组合物及其使用方法 | |
| JP7777988B2 (ja) | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 | |
| US20230265406A1 (en) | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same | |
| US20240270797A1 (en) | Coronavirus neutralizing compositions and associated methods | |
| Shaw et al. | Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4 | |
| CN101522715B (zh) | 针对可溶型lox-1的单克隆抗体 | |
| JP2024507220A (ja) | パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法 | |
| CN108350060A (zh) | 包含抗体结构域融合蛋白质的异聚体 | |
| IL322564A (en) | Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use | |
| CN117402243A (zh) | 抗Nectin-4抗体及其应用 | |
| JP2022542699A (ja) | カンジダ属に対する抗体およびその使用法 | |
| US12435157B2 (en) | Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers | |
| CA2911933A1 (en) | Pappalysin regulator | |
| US20240059759A1 (en) | Sars-cov(-2) spike glycoprotein-binding domains and polypeptides comprising the same and use of the same | |
| TW201437229A (zh) | 抗活化蛋白ｃ之人化單株抗體及其用途 |